<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">World J Surg Oncol</journal-id>
      <journal-id journal-id-type="iso-abbrev">World J Surg Oncol</journal-id>
      <journal-title-group>
        <journal-title>World Journal of Surgical Oncology</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1477-7819</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25551692</article-id>
      <article-id pub-id-type="pmc">4320576</article-id>
      <article-id pub-id-type="publisher-id">1877</article-id>
      <article-id pub-id-type="doi">10.1186/1477-7819-12-407</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Carcinosarcoma of native renal pelvis in recipient after a renal transplant: a case report</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Wu</surname>
            <given-names>Jitao</given-names>
          </name>
          <address>
            <email>JitaoWuwjt@163.com</email>
          </address>
          <xref ref-type="aff" rid="Aff5"/>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Wang</surname>
            <given-names>Xuyun</given-names>
          </name>
          <address>
            <email>XuyunWangwxy@163.com</email>
          </address>
          <xref ref-type="aff" rid="Aff5"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lin</surname>
            <given-names>Chunhua</given-names>
          </name>
          <address>
            <email>ChunhuaLinlch@163.com</email>
          </address>
          <xref ref-type="aff" rid="Aff5"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Yu</surname>
            <given-names>Shengqiang</given-names>
          </name>
          <address>
            <email>ShengqiangYuysq@163.com</email>
          </address>
          <xref ref-type="aff" rid="Aff5"/>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Cai</surname>
            <given-names>Li</given-names>
          </name>
          <address>
            <email>LiCaicailicl@163.com</email>
          </address>
          <xref ref-type="aff" rid="Aff6"/>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Gao</surname>
            <given-names>Zhenli</given-names>
          </name>
          <address>
            <email>ZhenliGaogzl@163.com</email>
          </address>
          <xref ref-type="aff" rid="Aff5"/>
        </contrib>
        <aff id="Aff5"><label/>Department of Urology, Yantai Yuhuangding Hospital, No.20 East Yuhuangding Road, Yantai, Shandong Province 264000 China </aff>
        <aff id="Aff6"><label/>Department of Pathology, Yantai Yuhuangding Hospital, No.20 East Yuhuangding Road, Yantai, Shandong Province 264000 China </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>30</day>
        <month>12</month>
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2014</year>
      </pub-date>
      <volume>12</volume>
      <elocation-id>407</elocation-id>
      <history>
        <date date-type="received">
          <day>14</day>
          <month>4</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>3</day>
          <month>12</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Wu et al.; licensee BioMed Central. 2014</copyright-statement>
        <license license-type="open-access">
          <license-p>This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Background</title>
          <p>Carcinosarcoma is a malignancy that rarely occurs in the renal pelvis.</p>
        </sec>
        <sec>
          <title>Materials and methods</title>
          <p>We present a case of histologically proven, native renal pelvis carcinosarcoma in a 65-year-old woman who had accepted a renal transplant. We performed a laparoscopic ureterectomy, combined with lymph node dissection and immunosuppression with sirolimus (SRL), which was alternated with the conventional immunosuppressant - cyclosporine.</p>
        </sec>
        <sec>
          <title>Results</title>
          <p>This patient was still alive 34&#xA0;months after renal transplantation.</p>
        </sec>
        <sec>
          <title>Conclusions</title>
          <p>Operation is still the best choice, and the SRL may be beneficial for preventing the progression of a tumor.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Carcinosarcoma</kwd>
        <kwd>Renal pelvis</kwd>
        <kwd>Renal transplantation</kwd>
        <kwd>Sirolimus</kwd>
        <kwd>Pulmonary cytomegalovirus infection</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s) 2014</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Background</title>
      <p>The overall incidence of <italic>de novo</italic> malignancies in renal transplant (RT) recipients is significantly higher than in the general population due to long-term immunosuppressive therapy and oncogenic viral infections [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. The malignant tumors of the transplanted kidney are mainly nonmelanoma skin cancers and malignancies, including post-transplant lymphoproliferative disorder and solid organ cancer [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. The prevalence and characteristics of post-transplant malignancies differ in various geographic areas. In western countries, the most common type of post-transplant urinary tract malignancy is renal cell carcinoma [<xref ref-type="bibr" rid="CR1">1</xref>]. In contrast, the majority of reported tumors in Chinese patients were urothelial carcinomas [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>], which occurred in 4.1% of all RT recipients and 47.6% of all patients with a post-transplant malignancy [<xref ref-type="bibr" rid="CR6">6</xref>]. Carcinosarcoma of the kidney and renal pelvis (CSKP) commonly presented as high-grade, advanced stage disease, and was associated with a poor prognosis regardless of location [<xref ref-type="bibr" rid="CR7">7</xref>].</p>
      <p>Carcinosarcoma of the renal pelvis is an extremely rare malignancy with a poor prognosis in the few reported cases [<xref ref-type="bibr" rid="CR8">8</xref>&#x2013;<xref ref-type="bibr" rid="CR11">11</xref>]. The carcinosarcoma of the renal pelvis in patients after renal transplantation is rarer. Here, we present a histologically proven case of carcinosarcoma of the left renal pelvis in renal transplant recipient.</p>
    </sec>
    <sec id="Sec2">
      <title>Case presentation</title>
      <p>A 65-year-old female patient developed chronic renal failure with unknown etiology and began hemodialysis in 2003. The patient denied past tobacco use or analgesic abuse. The patient received a renal transplantation in 2005 from a male cadaveric donor. Immunosuppressive therapy was applied using a triple immunosuppressive regimen, including cyclosporine (CsA), prednisone, and mycophenolate mofetil.The patient suffered from a pulmonary cytomegalovirus infection 8&#xA0;months after the renal transplantation, and took oral cyclosporine and prednisone for a combination immunosuppressive treatment after the transplant. She had normal renal function, and the serum creatinine levels were maintained at 0.62 to 0.88&#xA0;mg/dL. Forty-eight months after the renal transplantation, the patient went to the local hospital because of recurrent gross hematuria with waist pain on the left side. The CT examination revealed a left pelvic lesion of approximately 5&#xA0;cm&#x2009;&#xD7;&#x2009;4&#xA0;cm (Figure&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>). It was showed in the CT image that, irregular nodular soft tissue shadow filled in the left pelvis; the adjacent calyces and renal parenchyma were compressed; and there was no obvious swollen lymph gland shadow. Preoperative cystoscopy and chest computed tomography (CT) examinations revealed no abnormalities.A pathological examination showed that the size of the full-cut kidney and the surrounding fat capsule was 15&#xA0;cm&#x2009;&#xD7;&#x2009;10&#xA0;cm&#x2009;&#xD7;&#x2009;5&#xA0;cm, and the actual kidney size was 12&#xA0;cm&#x2009;&#xD7;&#x2009;7&#xA0;cm&#x2009;&#xD7;&#x2009;4&#xA0;cm. A bulging mass of 6&#xA0;cm&#x2009;&#xD7;&#x2009;4&#xA0;cm was observed at the renal pelvic cut surface without an envelope. This mass showed infiltrative growth that was gray and of fine quality, partly translucent and jelly-like, and also showed some hemorrhagic and necrotic areas. The renal parenchyma was atrophied and the ureteral length was 8&#xA0;cm. Microscopic observations revealed two tumor components. One was a high-grade urothelial carcinoma component with partial papillary arrangement, and the epithelial cells were mostly heterotypic and pleomorphic, with some of them falling off. The cell nucleus was obviously pleomorphic, deeply stained, and the nucleolus was prominent and visible with pathological mitotic figures. The other was a heterologous sarcomatous component with a malignant peripheral nerve sheath tumor (MPNST) structure, and this was the dominant component. The tumors showed a diffuse growth or formed an alternate distribution of cell-rich areas and cell-sparse areas. The sparse areas were associated with myxoid stroma. The blood vessels were surrounded by tumor cells. The cells were fusiform and polygonal, and the cytoplasm was abundant, with red staining. The nucleus was large, deeply stained and irregular, and the nucleolus was prominent, with visible mitotic figures, multifocal necrosis and hemorrhage. Part of the region showed urothelial carcinoma and MPNST component with a transitional phase (Figure&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>). According to the TNM classification system, the patient was diagnosed with stage pT3N0M0.An immunohistochemical examination showed that cytokeratin of the urothelial carcinoma was positive (Figure&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>). Vimentin was positive in the sarcoma, and was negative in the urothelial carcinoma (Figure&#xA0;<xref rid="Fig4" ref-type="fig">4</xref>). Some of the MPNST cells S-100 were positive in the carcinoma and sarcoma transition area, and strongly positive in the area of the sarcoma cells (Figure&#xA0;<xref rid="Fig5" ref-type="fig">5</xref>). Smooth muscle actin (SMA) of sarcoma cells was negative, and Human Melanoma Black (HMB45) and desmin were negative.<fig id="Fig1"><label>Figure 1</label><caption><p>
<bold>Computed tomography (CT) scan revealed a 5&#xA0;cm&#x2009;&#xD7;&#x2009;4&#xA0;cm lesion in the left pelvic region.</bold>
</p></caption><graphic xlink:href="12957_2014_1877_Fig1_HTML" id="d30e372"/></fig><fig id="Fig2"><label>Figure 2</label><caption><p>
<bold>Pathological examination of the lesion.</bold>
</p></caption><graphic xlink:href="12957_2014_1877_Fig2_HTML" id="d30e384"/></fig><fig id="Fig3"><label>Figure 3</label><caption><p>
<bold>Immunohistochemical examination of the cytokeratin.</bold>
</p></caption><graphic xlink:href="12957_2014_1877_Fig3_HTML" id="d30e396"/></fig><fig id="Fig4"><label>Figure 4</label><caption><p>
<bold>Immunohistochemical examination of the vimentin.</bold>
</p></caption><graphic xlink:href="12957_2014_1877_Fig4_HTML" id="d30e408"/></fig><fig id="Fig5"><label>Figure 5</label><caption><p>
<bold>Immunohistochemical examination of S-100.</bold>
</p></caption><graphic xlink:href="12957_2014_1877_Fig5_HTML" id="d30e420"/></fig></p>
      <p>The pathological diagnosis was that the left renal pelvic carcinosarcoma invaded the renal parenchyma, but was not involved the ureteral stump.</p>
      <p>The patient accepted laparoscopic ureterectomy combined with lymph node dissection in our hospital. The operation went well, and 7&#xA0;days after the operation, she was discharged from the hospital as she had recuperated. One week after the operation, she began to adjust the immunosuppressive regimen by using sirolimus (SRL) instead of cyclosporine, and the initial loading dose of SRL was 2&#xA0;mg and 1&#xA0;mg the next day, which was taken 4&#xA0;hours after meals. Regular monitoring of blood concentrations was carried out after the conversion, and the drug dosage was adjusted according to the blood concentration, to maintain a plasma concentration of 4 to 6&#xA0;&#x3BC;g/L of SRL. The patient refused to undergo any adjuvant therapy after the operation. She accepted regular postoperative follow-up. At the time of writing, 34&#xA0;months after the left kidney ureterectomy, she is still alive with normal renal function.</p>
    </sec>
    <sec id="Sec3" sec-type="discussion">
      <title>Discussion</title>
      <p>The overall incidence of <italic>de novo</italic> malignancies after RT is four to five times higher than that in the general population and has been estimated to be as high as 20% after 10&#xA0;years [<xref ref-type="bibr" rid="CR1">1</xref>]. According to the Cincinnati Transplant Tumor Registry, the most prevalent <italic>de novo</italic> neoplasms in organ transplant recipients are skin cancers and post-transplant lymphoproliferative disease [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. For urinary tract, renal cell carcinoma (RCC) was the most frequent tumor after RT in the west [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR5">5</xref>], with urothelium cancer being most frequent in China [<xref ref-type="bibr" rid="CR6">6</xref>]. The development of carcinosarcoma is well documented in the mammary gland, the larynx and the uterus. Less frequently, development in bladder, esophageal, lung and kidney has been reported. Fewer than twenty cases of carcinosarcoma of the pelvis have been described in the literature.</p>
      <p>Carcinosarcoma is often difficult to distinguish from sarcomatoid carcinoma. Carcinosarcomas are composed of epithelial and sarcomatous components, and sarcomatoid carcinomas are malignant spindle cell neoplasms composed of epithelial components containing changes of sarcomatoid morphology [<xref ref-type="bibr" rid="CR12">12</xref>]. Microscopically, the carcinomatous component is mostly transitional cell carcinoma and the sarcomatous component is largely composed of spindle or pleomorphic tumor giant-cells. Carcinosarcomas and sarcomatoid carcinomas are similar on hematoxylineosin staining, so immunohistochemical study is mandatory for diagnosis. In this case, epithelial component expressed cytokeratins while sarcomatous component vimentin and S-100. The pathological diagnosis is confirmed.</p>
      <p>Exact survival rate remains a matter of controversy due to a lack of consistent long-term follow-up. Wang <italic>et al.</italic> reviewed the carcinosarcoma involving kidney and renal pelvis, and the median cancer specific survival was 6&#xA0;months and the 1-year cancer specific survival rate for the entire cohort was 30.2% [<xref ref-type="bibr" rid="CR7">7</xref>]. In the present report, this patient is still alive (&gt;34&#xA0;months) with normal renal function and no metastasis. This survival may be because regular follow-up allowed for diagnosis and treatment of the tumor in an early stage and because SRL instead of cyclosporine may have suppressed the progression of tumor. Hojo <italic>et al.</italic> has reported that cyclosporine can promote cancer progression by a direct cellular effect that is independent of its effect on the host&#x2019;s immune cells, and that cyclosporine-induced transforming growth factor-beta (TGF-beta) production is involved in this [<xref ref-type="bibr" rid="CR13">13</xref>]. That is to say, cyclosporine can also promote cancer progression directly. As is reported, when compared with cyclosporine, SRL induce adverse events more frequently, but the mean MDRD eGFR is higher for renal function [<xref ref-type="bibr" rid="CR14">14</xref>]. The reintroduction of calcineurin inhibitors is safe in patients who have been withdrawn from sirolimus owing to adverse effects [<xref ref-type="bibr" rid="CR15">15</xref>]. SRL, besides its antiangiogenic properties, has a strong tumor-specific functional effect on established tumor vessels [<xref ref-type="bibr" rid="CR16">16</xref>].</p>
      <p>Carcinosarcoma is rare in renal pelvis but progresses rapidly and has an unsatisfactory prognosis. The pathologic stage is the main predictor of patient survival. No direct correlation has been found with previous stone disease, infection, or radiation exposure and tumor development. Chemotherapy offers little response and no survival advantage [<xref ref-type="bibr" rid="CR17">17</xref>&#x2013;<xref ref-type="bibr" rid="CR20">20</xref>]. Treatment is early nephrectomy. For this, early diagnosis should be made. Transplanted and native kidneys should be screened for tumors by ultrasound after transplantation [<xref ref-type="bibr" rid="CR21">21</xref>]. Thus, tumors can be diagnosed at an early stage. RT recipients should do ultrasound and CT in regular postoperative follow-ups to allow for the diagnosis of carcinosarcoma at an early stage. Nonfunctioning native kidneys with suspicious lesions should be removed early [<xref ref-type="bibr" rid="CR5">5</xref>].</p>
    </sec>
    <sec id="Sec4" sec-type="conclusions">
      <title>Conclusion</title>
      <p>In conclusion, carcinosarcoma is rare in the renal pelvis, progresses rapidly and has an unsatisfactory prognosis. It is not sensitive to chemo-radiation. Operation is still the best choice, and the SRL may be beneficial for preventing the progression of the tumor. From a therapeutic and prognostic point of view, it is important to make a correct and early diagnosis.</p>
    </sec>
    <sec id="Sec5">
      <title>Consent</title>
      <p>Written informed consent was obtained from the patient for publication of this Case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.</p>
    </sec>
  </body>
  <back>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>CsA</term>
          <def>
            <p>cyclosporine</p>
          </def>
        </def-item>
        <def-item>
          <term>CSKP</term>
          <def>
            <p>carcinosarcoma of the kidney and renal pelvis</p>
          </def>
        </def-item>
        <def-item>
          <term>CT</term>
          <def>
            <p>computed tomography</p>
          </def>
        </def-item>
        <def-item>
          <term>MPNST</term>
          <def>
            <p>malignant peripheral nerve sheath tumor</p>
          </def>
        </def-item>
        <def-item>
          <term>RCC</term>
          <def>
            <p>renal cell carcinoma</p>
          </def>
        </def-item>
        <def-item>
          <term>RT</term>
          <def>
            <p>renal transplant</p>
          </def>
        </def-item>
        <def-item>
          <term>SRL</term>
          <def>
            <p>sirolimus.</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <fn-group>
      <fn>
        <p>
          <bold>Competing interests</bold>
        </p>
        <p>The authors declare that they have no competing interests.</p>
      </fn>
      <fn>
        <p>
          <bold>Authors&#x2019; contributions</bold>
        </p>
        <p>JW and XW participated in the design of this study, and they both performed the statistical analysis. CL and ZG carried out the study and, together with SY, collected important background information and drafted the manuscript. LC conceived of this study, participated in the design and helped to draft the manuscript. All authors read and approved the final manuscript.</p>
      </fn>
    </fn-group>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Penn</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>Occurrence of cancers in immunosuppressed organ transplant recipients</article-title>
          <source>Clin Transpl</source>
          <year>1994</year>
          <volume>1994</volume>
          <fpage>99</fpage>
          <lpage>109</lpage>
          <pub-id pub-id-type="pmid">7547597</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Penn</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>Post-transplant malignancy</article-title>
          <source>Drug Saf</source>
          <year>2000</year>
          <volume>23</volume>
          <fpage>101</fpage>
          <lpage>113</lpage>
          <pub-id pub-id-type="doi">10.2165/00002018-200023020-00002</pub-id>
          <pub-id pub-id-type="pmid">10945373</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Navarro</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Lopez-Andreu</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Rodriguez-Benot</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Aguera</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Del Castillo</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Aljama</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Cancer incidence and survival in kidney transplant patients</article-title>
          <source>Transplant Proc</source>
          <year>2008</year>
          <volume>40</volume>
          <fpage>2936</fpage>
          <lpage>2940</lpage>
          <pub-id pub-id-type="doi">10.1016/j.transproceed.2008.09.025</pub-id>
          <pub-id pub-id-type="pmid">19010153</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Morath</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Mueller</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Goldschmidt</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Schwenger</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Opelz</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Zeier</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Malignancy in renal transplantation</article-title>
          <source>J Am Soc Nephrol</source>
          <year>2004</year>
          <volume>15</volume>
          <fpage>1582</fpage>
          <lpage>1588</lpage>
          <pub-id pub-id-type="doi">10.1097/01.ASN.0000126194.77004.9B</pub-id>
          <pub-id pub-id-type="pmid">15153569</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Melchior</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Franzaring</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Shardan</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Schwenke</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Pl&#xFC;mpe</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Schnell</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Dreikorn</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Urological de novo malignancy after kidney transplantation: a case for the urologist</article-title>
          <source>J Urol</source>
          <year>2011</year>
          <volume>185</volume>
          <fpage>428</fpage>
          <lpage>432</lpage>
          <pub-id pub-id-type="doi">10.1016/j.juro.2010.09.091</pub-id>
          <pub-id pub-id-type="pmid">21167532</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Qu</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>X</given-names>
            </name>
          </person-group>
          <article-title>Clinical analysis of urothelial cancer after renal transplantation</article-title>
          <source>Beijing Da Xue Xue Bao</source>
          <year>2011</year>
          <volume>43</volume>
          <fpage>579</fpage>
          <lpage>581</lpage>
          <pub-id pub-id-type="pmid">21844971</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>FW</given-names>
            </name>
            <name>
              <surname>Kessinger</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>The natural history and outcomes of the patients with carcinosarcoma involving kidney and renal pelvis</article-title>
          <source>Adv Urol</source>
          <year>2011</year>
          <volume>2011</volume>
          <fpage>693964</fpage>
          <pub-id pub-id-type="doi">10.1155/2011/693964</pub-id>
          <pub-id pub-id-type="pmid">21785585</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dimitriou</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Gattuso</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Coogan</surname>
              <given-names>CL</given-names>
            </name>
          </person-group>
          <article-title>Carcinosarcoma of the renal pelvis</article-title>
          <source>Urology</source>
          <year>2000</year>
          <volume>56</volume>
          <fpage>508</fpage>
          <pub-id pub-id-type="doi">10.1016/S0090-4295(00)00660-9</pub-id>
          <pub-id pub-id-type="pmid">10962328</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yilmaz</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Birlik</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Arican</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Guney</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Carcinosarcoma of the renal pelvis and urinary bladder: a case report</article-title>
          <source>Korean J Radiol</source>
          <year>2003</year>
          <volume>4</volume>
          <fpage>255</fpage>
          <lpage>259</lpage>
          <pub-id pub-id-type="doi">10.3348/kjr.2003.4.4.255</pub-id>
          <pub-id pub-id-type="pmid">14726644</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Deshmukh</surname>
              <given-names>SD</given-names>
            </name>
            <name>
              <surname>Gaopande</surname>
              <given-names>VL</given-names>
            </name>
            <name>
              <surname>Pande</surname>
              <given-names>DP</given-names>
            </name>
            <name>
              <surname>Pathak</surname>
              <given-names>GS</given-names>
            </name>
            <name>
              <surname>Kulkarni</surname>
              <given-names>BK</given-names>
            </name>
          </person-group>
          <article-title>Carcinosarcoma of renal pelvis with immunohistochemical correlation</article-title>
          <source>Gulf J Oncol</source>
          <year>2012</year>
          <volume>12</volume>
          <fpage>65</fpage>
          <lpage>69</lpage>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chiu</surname>
              <given-names>KC</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Liang</surname>
              <given-names>YC</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>CY</given-names>
            </name>
          </person-group>
          <article-title>Renal carcinosarcoma: case report and review of literature</article-title>
          <source>Ren Fail</source>
          <year>2008</year>
          <volume>30</volume>
          <fpage>1034</fpage>
          <lpage>1039</lpage>
          <pub-id pub-id-type="doi">10.1080/08860220802403192</pub-id>
          <pub-id pub-id-type="pmid">19016157</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hisataki</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Takahashi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Taguchi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Shimizu</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Suzuki</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Takatsuka</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Iwaki</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Sarcomatoid transitional cell carcinoma originating from a duplicated renal pelvis</article-title>
          <source>Int J Urol</source>
          <year>2001</year>
          <volume>8</volume>
          <fpage>704</fpage>
          <lpage>706</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1442-2042.2001.00396.x</pub-id>
          <pub-id pub-id-type="pmid">11851772</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hojo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Morimoto</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Maluccio</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Asano</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Morimoto</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Lagman</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Shimbo</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Suthanthiran</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Cyclosporine induces cancer progression by a cell-autonomous mechanism</article-title>
          <source>Nature</source>
          <year>1999</year>
          <volume>397</volume>
          <fpage>530</fpage>
          <lpage>534</lpage>
          <pub-id pub-id-type="doi">10.1038/17401</pub-id>
          <pub-id pub-id-type="pmid">10028970</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lebranchu</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Snanoudj</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Toupance</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Weestel</surname>
              <given-names>PF</given-names>
            </name>
            <name>
              <surname>De Ligny</surname>
              <given-names>BH</given-names>
            </name>
            <name>
              <surname>Buchler</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Rerolle</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Thierry</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Moulin</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Subra</surname>
              <given-names>JF</given-names>
            </name>
          </person-group>
          <article-title>Five&#x2012;year results of a randomized trial comparing de novo sirolimus and cyclosporine in renal transplantation: the spiesser study</article-title>
          <source>Am J Transplant</source>
          <year>2012</year>
          <volume>12</volume>
          <fpage>1801</fpage>
          <lpage>1810</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1600-6143.2012.04036.x</pub-id>
          <pub-id pub-id-type="pmid">22486815</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Garrouste</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Kamar</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Guilbeau-Frugier</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Guitard</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Esposito</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Lavayssiere</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Nogier</surname>
              <given-names>M-B</given-names>
            </name>
            <name>
              <surname>Cointault</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Ribes</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Rostaing</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Long-term results of conversion from calcineurin inhibitors to sirolimus in 150 maintenance kidney transplant patients</article-title>
          <source>Exp Clin Transplant</source>
          <year>2012</year>
          <volume>10</volume>
          <fpage>110</fpage>
          <lpage>118</lpage>
          <pub-id pub-id-type="doi">10.6002/ect.2011.0116</pub-id>
          <pub-id pub-id-type="pmid">22432753</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Guba</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Yezhelyev</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Eichhorn</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Schmid</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Ischenko</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Papyan</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Graeb</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Seeliger</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Geissler</surname>
              <given-names>EK</given-names>
            </name>
            <name>
              <surname>Jauch</surname>
              <given-names>K-W</given-names>
            </name>
          </person-group>
          <article-title>Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF</article-title>
          <source>Blood</source>
          <year>2005</year>
          <volume>105</volume>
          <fpage>4463</fpage>
          <lpage>4469</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2004-09-3540</pub-id>
          <pub-id pub-id-type="pmid">15671443</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lopez-Beltran</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Escudero</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Cavazzana</surname>
              <given-names>AO</given-names>
            </name>
            <name>
              <surname>Spagnoli</surname>
              <given-names>LG</given-names>
            </name>
            <name>
              <surname>Vicioso-Recio</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Sarcomatoid transitional cell carcinoma of the renal pelvis. A report of five cases with clinical, pathological, immunohistochemical and DNA ploidy analysis</article-title>
          <source>Pathol Res Pract</source>
          <year>1996</year>
          <volume>192</volume>
          <fpage>1218</fpage>
          <lpage>1224</lpage>
          <pub-id pub-id-type="doi">10.1016/S0344-0338(96)80154-3</pub-id>
          <pub-id pub-id-type="pmid">9182292</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Acikalin</surname>
              <given-names>MF</given-names>
            </name>
            <name>
              <surname>Kabukcuoglu</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Can</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Sarcomatoid carcinoma of the renal pelvis with giant cell tumor&#x2012;like features: case report with immunohistochemical findings</article-title>
          <source>Int J Urol</source>
          <year>2005</year>
          <volume>12</volume>
          <fpage>199</fpage>
          <lpage>203</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1442-2042.2005.01002.x</pub-id>
          <pub-id pub-id-type="pmid">15733116</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Petsch</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Planz</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Tschahargane</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Caspers</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Primary sarcomatoid carcinoma of the ureter</article-title>
          <source>Aktuelle Urol</source>
          <year>2004</year>
          <volume>35</volume>
          <fpage>137</fpage>
          <lpage>139</lpage>
          <pub-id pub-id-type="doi">10.1055/s-2004-818363</pub-id>
          <pub-id pub-id-type="pmid">15146379</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thiel</surname>
              <given-names>DD</given-names>
            </name>
            <name>
              <surname>Igel</surname>
              <given-names>TC</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>KJ</given-names>
            </name>
          </person-group>
          <article-title>Sarcomatoid carcinoma of transitional cell origin confined to renal pelvis</article-title>
          <source>Urology</source>
          <year>2006</year>
          <volume>67</volume>
          <fpage>622</fpage>
          <pub-id pub-id-type="doi">10.1016/j.urology.2005.09.026</pub-id>
          <pub-id pub-id-type="pmid">16504263</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>K&#xE4;lble</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Lucan</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Nicita</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Sells</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Revilla</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Wiesel</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>EAU guidelines on renal transplantation</article-title>
          <source>Eur Urol</source>
          <year>2005</year>
          <volume>47</volume>
          <fpage>156</fpage>
          <lpage>166</lpage>
          <pub-id pub-id-type="doi">10.1016/j.eururo.2004.02.009</pub-id>
          <pub-id pub-id-type="pmid">15661409</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
